Low-dose indinavir in combination with low-dose ritonavir: Steady-state pharmacokinetics and long-term clinical outcome follow-up

HIV Medicine

Volumn 4, Issue 3, 2003, Pages 250-254

  Justesen, Ulrik Stenz ^a   Levring, A M ^b   Thomsen, A ^b   Lindberg, J A ^b   Pedersen, C ^c   Tauris, P ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b HERNING HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Combination therapy; Efficacy; Indinavir; Pharmacokinetics; RTV

Indexed keywords

ANTIRETROVIRUS AGENT; DIAZEPAM; INDINAVIR; METHADONE; NITRAZEPAM; OLANZAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SERTRALINE; VIRUS RNA;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; METABOLIC DISORDER; NAUSEA AND VOMITING; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN TOXICITY; STEADY STATE; SWEATING; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0041631061     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2003.00153.x     Document Type: Article

References (15)

1. Mellors JW, Munoz A, Giorgi JV et al. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection Ann Intern Med 1997; 126: 946-954.
2. Demeter LM, Hughes MD, Coombs RW et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-733.
3. Gulick RM, Mellors JW, Havlir D et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000; 133: 35-39.
4. van Heeswijk RP, Veldkamp AI, Hoetelmans RM et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13: F95-F99.
5. Burger DM, Hugen PW, Aarnoutse RE et al. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy J Acquir Immune Defic Syndr 2001; 26: 218-224.
6. Lichterfeld M, Nischalke HD, Bergmann F et al. Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy. HIV Med 2002; 3: 37-43.
7. Lamotte C, Peytavin G, Perre P el al. Increasing adverse events (AE) with indinavir (IDV) dosages and plasma concentrations in four different ritonavir (RTV) -IDV containing regimen in HIV-infected patients. 2nd International Workshop on Clinical Pharmacology of HIV Therapy Noordwijk, The Netherlands, April 2001 [Abstract 4.1].
8. Solas C, Basso S, Poizot-Martin I et al. High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. Acquir Immune Defic Syndr 2002; 29: 374-377.
9. Cahn P, Casiró A, Puentes T et al. Continuing indinavir (800 mg tid) versus switching to indinavir + ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression. A randomized study: the bid efficacy and safety trial. The 1st IAS Conference on HIV Pathogenesis and Treatment Buenos Aires, Argentina, July 2001 [Abstract 60].
10. Bak-Dragsted U, Benetucci J, Bruun JN et al. A phase IV randomized open-label, multicenter trial to evaluate safety and efficacy of Indinavir/Ritonavir (800/100 MG BID) vs Saquinavir/Ritonavir (1000/100 MG BID) in adult HIV-1 infection: the maxcmin 1 trial. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection Athens, Greece, October 2001 [Abstract O10].
11. Katlama C, Lamotte C, Ait-Mohand H et al. Ritonavir (RTV) / indinavir (IDV) (100/400 Mg bid): a simple, effective and well tolerated PI containing regimen. The 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, July 2001 [Abstract 214].
12. Aarnoutse R, Burger D, Verweij-Van Wissen C, Van Ewijk-Beneken Kolmer E, Wuis E, Hekster Y. An international interlaboratory quality control (QC) program for therapeutic drug monitoring (TDM) in HIV infection. 8th Conference on Retroviruses and Opportunistic Infections Chicago, February 2001 [Abstract 734].
13. Justesen US, Pedersen C, Klitgaard NA. Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography. J Chromatogr B Anal Technol Biomed Life Sci 2003; 783: 491-500.
14. Khoo SH, Gibbons SE, Back DJ. Therapeutic drug monitoring as a tool in treating HIV infection. AIDS 2001; 15 (Suppl. 5): S171-S181.
15. Justesen US, Pedersen C. Diurnal variation of plasma protease inhibitor concentrations. AIDS 2002; 16: 2487-2489.